We’ve recently updated our valuation analysis.

Spago Nanomedical Valuation

Is SPAGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SPAGO?

Other financial metrics that can be useful for relative valuation.

SPAGO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SPAGO's PS Ratio compare to its peers?

The above table shows the PS ratio for SPAGO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average30.6x
LPGO Lipigon Pharmaceuticals
52.6x36.7%kr25.3m
VIVE Vivesto
21.8x14.5%kr250.2m
PROGEN Prostatype Genomics
36.4xn/akr40.6m
AEGIR AegirBio
11.4xn/akr107.5m
SPAGO Spago Nanomedical
10.6x58.0%kr65.3m

Price-To-Sales vs Peers: SPAGO is good value based on its Price-To-Sales Ratio (10.6x) compared to the peer average (30.6x).


Price to Earnings Ratio vs Industry

How does SPAGO's PE Ratio compare vs other companies in the SE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a47.4%
n/an/an/a

Price-To-Sales vs Industry: SPAGO is good value based on its Price-To-Sales Ratio (10.6x) compared to the Swedish Biotechs industry average (19.4x)


Price to Sales Ratio vs Fair Ratio

What is SPAGO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SPAGO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.6x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: SPAGO is expensive based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).


Share Price vs Fair Value

What is the Fair Price of SPAGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SPAGO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SPAGO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies